Do not substitute sterile water for injection unless you plan to use the entire vial in a single session
SURMOUNT-1 clinical trial showed mean % weight losses at week 72 were 15% (95% CI 15.9 to 14.2), 19.5% (95% CI 20.4 to 18.5), 20.9% (95% CI 21.8 to 19.9) and 3.1% (95% CI 4.3 to 1.9) with 5 mg/week, 10 mg/week, 15 mg/week Tirzepatide and placebo, respectively ( p 5% weight at six months
[4] evaluated the distribution of GLP-1R in human brains and demonstrated its presence in all neurons of the parietal cortex, in the ARC, PVN, VMN, area postrema, dorsal motor nucleus of the vagus in the medulla oblongata, and in the NTS
Gedalia built TrufaMED around physician-led protocols, Joint Commission accreditation, and a standard of care usually reserved for hospital systems
Treatment recommendations are based on medical history, clinical appropriateness, and provider discretion.
Tirzepatide may have serious side effects, including possible thyroid tumors